Bommelaer, G, Dorval, E, Denis, P, et al. Prevalence of irritable bowel syndrome in the French population according to the Rome I criteria. Gastroenterol Clin Biol 2002;26: 1118–11123.
Hillila, MT, Farkkila, MA. Prevalence of irritable bowel syndrome according to different diagnostic criteria in a non-selected adult population. Aliment Pharmacol Ther 2004;20: 339–345.
Lu, CL, Chen, CY, Lang, HC, et al. Current patterns of irritable bowel syndrome in Taiwan: The Rome II questionnaire on a Chinese population. Aliment Pharmacol Ther 2003;18: 1159–1169.
Mitchell, CM, Drossman, DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987;92: 1282–1284.
Talley, NJ, Gabriel, SE, Harmsen, WS, et al. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995;109: 1736–1741.
Whitehead, WE, Burnett, CK, Cook, EW, 3rd, et al. Impact of irritable bowel syndrome on quality of life. Dig Dis Sci 1996;41: 2248–2253.
Sandler, RS, Stewart, WF, Liberman, JN, et al. Abdominal pain, bloating, and diarrhea in the United States: Prevalence and impact. Dig Dis Sci 2000;45: 1166–1171.
Boyce, PM, Koloski, NA, Talley, NJ. Irritable bowel syndrome according to varying diagnostic criteria: Are the new Rome II criteria unnecessarily restrictive for research and practice? Am J Gastroenterol 2000;95: 3176–3183.
Mearin, F, Badia, X, Balboa, A, et al. Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: Comparison of Rome II versus previous criteria in a general population. Scand J Gastroenterol 2001;36: 1155–1161.
Saito, YA, Locke, GR, Talley, NJ, et al. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000;95: 2816–2824.
Hoover, WW, Gerlach, EH, Hoban, DJ, et al. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 1993;16: 111–118.
Gillis, JC, Brogden, RN. Rifaximin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49: 467–484.
Di Stefano, M, Malservisi, S, Veneto, G, et al. Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2000;14: 551–556.
Di Stefano, M, Strocchi, A, Malservisi, S, et al. Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther 2000;14: 1001–1008.
Latella, G, Pimpo, MT, Sottili, S, et al. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003;18: 55–62.
Bond, JH, Jr, Levitt, MD, Prentiss, R. Investigation of small bowel transit time in man utilizing pulmonary hydrogen (H2) measurements. J Lab Clin Med 1975;85: 546–555.
Joseph, F, Jr, Rosenberg, AJ. Breath hydrogen testing: Diseased versus normal patients. J Pediatr Gastroenterol Nutr 1988;7: 787–788.
Kerlin, P, Wong, L. Breath hydrogen testing in bacterial overgrowth of the small intestine. Gastroenterology 1988;95: 982–988.
Rhodes, JM, Middleton, P, Jewell, DP. The lactulose hydrogen breath test as a diagnostic test for small-bowel bacterial overgrowth. Scand J Gastroenterol 1979;14: 333–336.
Chiarioni, G, Scattolini, C, Bonfante, F, et al. Effect of nifedipine on mouth-to-cecum transit of liquid meal in normal subjects. Dig Dis Sci 1993;38: 1022–1025.
Patel, VP, Jain, NK, Pitchumoni, CS. Factors affecting fasting breath hydrogen levels in healthy adults: A study in two continents. Am J Gastroenterol 1986;81: 771–773.
Brigidi, P, Swennen, E, Rizzello, F, et al. Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother 2002;14: 290–295.
De Leo, C, Eftimiadi, C, Schito, GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986;12: 979–981.
Pimentel, M, Chow, EJ, Lin, HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003;98: 412–419.
Hasler, WL. Lactulose breath testing, bacterial overgrowth, and IBS: Just a lot of hot air? Gastroenterology 2003;125: 1898–1900; discussion 1900.
Vernia, P, Camillo, MD, Marinaro, V, et al. Effect of predominant methanogenic flora on the outcome of lactose breath test in irritable bowel syndrome patients. Eur J Clin Nutr 2003;57: 1116–1119.
King, TS, Elia, M, Hunter, JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998;352: 1187–1189.
Kim, HJ, Camilleri, M, McKinzie, S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17: 895–904.
Nobaek, S, Johansson, ML, Molin, G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95: 1231–1238.
Nayak, AK, Karnad, DR, Abraham, P, et al. Metronidazole relieves symptoms in irritable bowel syndrome: The confusion with so-called ‘chronic amebiasis.' Indian J Gastroenterol 1997;16: 137–139.
O'Sullivan, MA, O'Morain, CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000;32: 294–301.
Balsari, A, Ceccarelli, A, Dubini, F, et al. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982;5: 185–194.
DuPont, HL, Jiang, ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 2004;10: 1009–1011.
Marchese, A, Salerno, A, Pesce, A, et al. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 2000;46: 253–266.